The device uses infrared beams to non-invasively assess glycated nail keratin. Image credit: Glyconics

A device that measures sugar levels stored in fingernails could be used to identify an individual’s risk of type 2 diabetes, according to studies published at the American Diabetes Association (ADA) annual meeting 2023, held from 23-26 June.

The Glyconics-DS device, developed by Glyconics, uses infrared beams to non-invasively assess glycated nail keratin. A cloud-based, predictive algorithm then transforms parameters into meaningful measurements.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Norwich, UK-based company says it has shrunk spectroscopy technology, which usually requires laboratory settings, into a point-of-care, handheld device.

The lack of a needle for a blood fingerpick test also means there is no need for single-use plastics when using the device.

The company has successfully completed two clinical studies – one conducted in the UK (NCT05198895), and the other in Spain (NCT05476016) – investigating the accuracy of its device in identifying diabetes risk. The studies were controlled by measuring HbA1c – a glycaemia biomarker.

In a statement announcing the results of the studies, Glyconics said it is planning to conduct a pivotal, larger-scale study – ANODE03 – later in 2023, to help support future regulatory approval.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A model by GlobalData estimates that the diabetes device market will be worth $33bn by 2030.

“Developing non-invasive systems for population-level screening will be an important tool in changing the paradigm of screening by reducing current barriers and identifying people at risk early,” said Professor Xavier Cos, chairman of Primary Care Diabetes Europe (PCDE) and lead investigator of the study in Spain.

“Early detection and treatment, which are key to better long-term outcomes, require more attention: This exciting new approach will shape the pivotal role that primary care plays in the management of diabetes and its long-term outcomes.”